All News
Filter News
Found 308 articles
-
Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
4/2/2018
Vaxart, Inc. announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine will be highlighted in an oral presentation at the World Vaccine Congress (WVC), taking place from April 2-5, 2018 in Washington, D.C.
-
Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
3/7/2018
Issued Claims Cover High Yield Production Process of Phase 2 Antiviral
-
Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc.
2/14/2018
In connection with the merger, Aviragen Therapeutics, Inc. changed its name to Vaxart, Inc. and effected a 1-for-11 reverse split of its common stock.
-
Vaxart Provides Merger Update
2/12/2018
Vaxart announced today it has reached an understanding with the CAS Group under which East Hill, a major shareholder in Aviragen, will support the merger between Vaxart and Aviragen.
-
Aviragen Adjourns Special Meeting of Stockholders to Allow Stockholders to Consider Improved Merger Deal Terms
2/12/2018
The Company filed a Form 8-K on February 7, 2018, which describes the improved deal terms.
-
CAS Group Supports Improved Vaxart Merger and Enters Into Agreement With Aviragen
2/12/2018
The Company previously announced that the special meeting of Aviragen stockholders, originally scheduled for February 6, 2018.
-
Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders
2/8/2018
Under the new terms, Aviragen stockholders would now own 49% of the combined company, up from 40% under the previous agreement.
-
Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018
2/7/2018
Aviragen intends to reconvene the Special Meeting on February 9, 2018 at 12:00 pm EST.
-
Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase II Challenge Study
2/1/2018
Vaxart announced today that its investigational H1 influenza oral tablet vaccine demonstrated a statistically significant reduction in the rate of influenza infection compared with placebo, and compared favorably with the market-leading injectable quadrivalent influenza vaccine (QIV) in a Phase 2 challenge trial.
-
Aviragen Provides New Information Supporting Vote FOR Vaxart Merger
2/1/2018
The voting period will close at the upcoming Special Meeting of Stockholders on February 6, 2018.
-
Vaxart Issues Statement Regarding Proposed Merger With Aviragen
2/1/2018
The following is a statement from Wouter Latour, M.D., Chief Executive Officer of Vaxart, who will lead the combined company following completion of the transaction:
-
CAS Group Announces Glass Lewis Recommendation That Aviragen Stockholders Vote AGAINST Merger and Emphasizes Value of Teslexivir (BTA074) Program
1/31/2018
CAS Group Supports the BTA074 Program and Considers it a Valuable Asset of Aviragen.
-
Aviragen Comments on ISS Report
1/29/2018
ISS’s recommendation relies on “the hope that the board finds another transaction that adequately compensates shareholders for Aviragen's assets.
-
ISS Recommends Aviragen Stockholders Vote AGAINST the Vaxart Merger on the CAS Group's BLUE Proxy Card
1/29/2018
In reaching its conclusion, ISS performed a detailed review of both sides' positions in the election contest as well as its own thorough independent analysis.
-
Aviragen Therapeutics Issues Letter to Stockholders
1/24/2018
The letter urged stockholders to vote FOR the Company’s proposed merger with Vaxart at its Special Meeting of Stockholders on February 6, 2018.
-
CAS Group Delivers Letter to the Stockholders of Aviragen
1/24/2018
Digirad , East Hill Management Company, LLC and Thomas M. Clay, are significant stockholders of Aviragen, and collectively beneficially own in the aggregate approximately 8.3% of AVIR's outstanding shares of common stock, delivered a letter to the stockholders of AVIR today.
-
Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart
1/12/2018
The Company notes that the transaction maximizes the value of Aviragen.
-
Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase II Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
11/29/2017
The Company expects to report top-line data from this trial in the second quarter of 2018.
-
Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results
11/2/2017
The Company reported a net loss of $5.3 million for the three month period ended September 30, 2017, as compared to a net loss of $10.0 million in the same quarter of the prior fiscal year.
-
Vaxart Announces Positive Safety and Immunogenicity Results for Its Oral Norovirus Vaccine in A Phase 1b Clinical Study
10/31/2017
The norovirus tablet vaccine was generally well tolerated in all subjects. Adverse events (AEs) were mostly mild in severity with headache as the most frequent AE.